Refine
Has Fulltext
- yes (18)
Is part of the Bibliography
- yes (18)
Year of publication
- 2021 (18) (remove)
Document Type
- Journal article (9)
- Doctoral Thesis (9)
Keywords
- DNA damage (2)
- DNA repair (2)
- Herzhypertrophie (2)
- biomedicine, general (2)
- cAMP (2)
- environmental health (2)
- occupational medicine/industrial medicine (2)
- pharmacology/toxicology (2)
- 3R (1)
- Bioluminescence resonance energy transfer (1)
- Biomarker (1)
- CaMKII (1)
- Celecoxib (1)
- Cell death and comet assay (1)
- Cyclo-AMP (1)
- DNS-Schädigung (1)
- Dimerisierung (1)
- ERK-Kaskade (1)
- ERK-cascade (1)
- ERK1/2 (1)
- FRET (1)
- Förster Resonanz Energie Transfer (1)
- G-Protein gekoppelte Rezeptoren (1)
- G-protein-coupled receptors (1)
- GPCR (1)
- Genotoxicity (1)
- Genotoxizität (1)
- High-thropughput screening (1)
- Hochdurchsatz-Screening (1)
- Huh6 (1)
- Hypertonie (1)
- In-silico Modell (1)
- Insulin (1)
- Interferenz (1)
- Kleinkern (1)
- Kognitive Beeinträchtigung (1)
- Lasiocarpin (1)
- Lebendzellmikroskopie (1)
- MAP-Kinase (1)
- Micronucleus (1)
- Mikrokern (1)
- Mundschleimhautzellen (1)
- Mutagenität (1)
- Oxidativer Stress (1)
- PDE (1)
- PDE2 (1)
- Phosphodiesterase (1)
- Pyrrolizidinalkaloide (1)
- Receptor dynamics (1)
- SCN5a (1)
- Senecionin (1)
- Seneciphyllin (1)
- Systembiologie (1)
- Thebain (1)
- alternative methods (1)
- arrhythmia (1)
- biomarker of exposure (1)
- blood samples (1)
- cardiac hypertrophy (1)
- comet assay (1)
- compartments (1)
- conduction disease (1)
- danio rerio (1)
- familial DCM (1)
- genotoxicity (1)
- glucuronide (1)
- heart failure (1)
- huh6 (1)
- human biomonitoring (1)
- in-silico model (1)
- lasiocarpine (1)
- mercapturic acid (1)
- mutation triggers (1)
- mycotoxin (1)
- ochratoxin A (1)
- organ toxicity (1)
- phosphorylation (1)
- senecionine (1)
- seneciphylline (1)
- transgenic animals (1)
- γ-H2AX (1)
Institute
- Institut für Pharmakologie und Toxikologie (18) (remove)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 965286 (1)
- QLK1-2001-01614 (1)
ERK1/2 are known key players in the pathophysiology of heart failure, but the members of the ERK cascade, in particular Raf1, can also protect the heart from cell death and ischemic injury. An additional autophosphorylation (ERK1 at Thr208, ERK2 at Thr188) empowers ERK1/2 translocation to the nucleus and phosphorylation of nuclear targets which take part in the development of cardiac hypertrophy. Thereby, targeting this additional phosphorylation is a promising pharmacological approach.
In this thesis, an in silico model of ERK cascade in the cardiomyocyte is introduced. The model is a semi-quantitive model and its behavior was tested with different softwares (SQUAD and CellNetAnalyzer). Different phosphorylation states of ERK1/2 as well as different stimuli can be reproduced. The different types of stimuli include hypertrophic as well as non-hypertrophic stimuli. With the introduced in-silico model time courses and synergistic as well as antagonistic receptor stimuli combinations can be predicted. The simulated time courses were experimentally validated. SQUAD was mainly used to make predictions about time courses and thresholds, whereas CNA was used to analyze steady states and feedback loops.
Furthermore, new targets of ERK1/2 which partially contribute, also in the formation of cardiac hypertrophy, were identified and the most promising of them were illuminated. Important further targets are Caspase 8, GAB2, Mxi-2, SMAD2, FHL2 and SPIN90.
Cardiomyocyte gene expression data sets were analyzed to verify involved components and to find further significantly altered genes after induced hypertrophy with TAC (transverse aortic constriction). Changes in the ultrastructure of the cardiomyocyte are the final result of induced hypertrophy.
G-protein-coupled receptors (GPCRs) regulate diverse physiological processes in the human body and represent prime targets in modern drug discovery. Engagement of different ligands to these membrane-embedded proteins evokes distinct receptor conformational rearrangements that facilitate subsequent receptor-mediated signalling and, ultimately, enable cellular adaptation to altered environmental conditions. Since the early 2000s, the technology of resonance energy transfer (RET) has been exploited to assess these conformational receptor dynamics in living cells and real time. However, to date, these conformational GPCR studies are restricted to single-cell microscopic setups, slowing down the discovery of novel GPCR-directed therapeutics. In this work, we present the development of a novel generalizable high-throughput compatible assay for the direct measurement of GPCR activation and deactivation. By screening a variety of energy partners for fluorescence (FRET) and bioluminescence resonance energy transfer (BRET), we identified a highly sensitive design for an α2A-adrenergic receptor conformational biosensor. This biosensor reports the receptor’s conformational change upon ligand binding in a 96-well plate reader format with the highest signal amplitude obtained so far. We demonstrate the capacity of this sensor prototype to faithfully quantify efficacy and potency of GPCR ligands in intact cells and real time. Furthermore, we confirm its universal applicability by cloning and validating five further equivalent GPCR biosensors. To prove the suitability of this new GPCR assay for screening purposes, we measured the well-accepted Z-factor as a parameter for the assay quality. All tested biosensors show excellent Z-factors indicating outstanding assay quality. Furthermore, we demonstrate that this assay provides excellent throughput and presents low rates of erroneous hit identification (false positives and false negatives). Following this phase of assay development, we utilized these biosensors to understand the mechanism and consequences of the postulated modulation of parathyroid hormone receptor 1 (PTHR1) through receptor activity-modifying protein 2 (RAMP2). We found that RAMP2 desensitizes PTHR1, but not the β2-adrenergic receptor (β2AR), for agonist-induced structural changes. This generalizable sensor design offers the first possibility to upscale conformational GPCR studies, which represents the most direct and unbiased approach to monitor receptor activation and deactivation. Therefore, this novel technology provides substantial advantages over currently established methods for GPCR ligand screening. We feel confident that this technology will aid the discovery of novel types of GPCR ligands, help to identify the endogenous ligands of so-called orphan GPCRs and deepen our understanding of the physiological regulation of GPCR function.